Tecvayli
The Top Pharma List rankings are compiled from GlobalData’s pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. Listed below are the charts and positions for Tecvayli in this year’s pharmaceutical sales data alongside recent articles on PMLiVE featuring Tecvayli.
28
2030 Global forecast Ranking
Recent articles on PMLiVE featuring Tecvayli
Approximately 10,500 people are diagnosed with bladder cancer every year in the UK
Approximately 5,900 new cases of the blood cancer are diagnosed every year in the UK
Approximately 5,900 new cases of the blood cancer are diagnosed every year in the UK
More than 35,000 cases of the blood cancer are expected to be diagnosed in the US this year
Tecvayli was the first BCMA-targeting bispecific antibody to be approved in Europe
More than 50,900 people in Europe were diagnosed with multiple myeloma in 2020
A phase 2 study demonstrated an overall response rate of 61.8% in Tecvayli-treated patients
Data provided by GlobalData
GlobalData provides trusted intelligence on the world’s largest industries including Pharmaceutical and Medical Devices. With over 2,000 in-house experts, our data-driven, technology-powered approach delivers gold-standard insights to help businesses navigate complex markets and predict future trends.
Our integrated platform empowers 4,000 of the world’s largest companies—including over 70% of FTSE 100 and 60% of Fortune 100 firms—to make timely, informed decisions through unique data, expert analysis, and innovative consulting solutions.
To find out more about how our research and insights can help you, please visit https://www.globaldata.com/who-we-are/why-globaldata/
For more details on the data and methodology used to create the Top Pharma Lists, please visit PMLiVE’s Top Pharma List – Methodology